InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (6 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
6
T+90 hit rate
0%
T+90 mean return
-43.0%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by JANNEY DANIEL, Director. Insider active across 3 companies, notably Esperion Therapeutics, Inc.. Cumulatively, 9 filings have been published. Breakdown: 1 buy · 6 sells. Total volume traded: €21.9m. History available since 27 May 2021. The latest transaction was disclosed on 8 June 2023 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations9 total
4,604 shares@ US$127.95782.8% of flowCommon StockSEC:0001711279-23-000046:0
50,000 shares@ US$95.023722.6% of flowCommon StockSEC:0001711279-23-000042:0
17,100 shares@ US$90.73567.3% of flowCommon StockSEC:0001711279-23-000035:0
7,900 shares@ US$90.31563.3% of flowCommon StockSEC:0001711279-23-000023:0
475,000 shares@ US$5.02100.0% of flowCommon StockSEC:0001209191-22-051141:0
Ideal exit: 18 Jun 2023 (T+270)
100,000 shares@ US$70.500.087% mcap50.0% of flowCommon StockSEC:0000899243-21-048122:0
100,000 shares@ US$70.5032.0% of flowCommon StockSEC:0000899243-21-048122
12,376 shares0Common StockSEC:0001628280-21-011356
12,376 shares0Common StockSEC:0001628280-21-011356:0
9 of 9 declarations
About JANNEY DANIEL
Daniel Janney serves as a Director at Esperion Therapeutics, Inc. and Krystal Biotech, Inc. In this role, he contributes to the strategy and governance of the companies. His expertise in the biopharmaceutical sector is an asset to the board.
